An Open, Single-center, Phase II Study of Sintilimab, Peg-aspargase Plus Anlotinib "Sandwich"With Radiotherapy in Previously Untreated Stage I-II Extranodal NK/T Cell Lymphoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Jun 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Catequentinib (Primary) ; Pegaspargase (Primary) ; Sintilimab (Primary)
Indications Extranodal NK-T-cell lymphoma
Focus Therapeutic Use

06 Jun 2022 Status changed from recruiting to completed.
08 Jun 2021 Results (n=39)evaluating efficacy and safety of sandwich chemoradiotion of sintilimab combined with anlotinib and pegaspargase (PEG-ASP) in newly diagnosed localized NKTL pts presented at the 57th Annual Meeting of the American Society of Clinical Oncology
19 May 2019 Status changed from active, no longer recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com